samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable
DESCRIPTION
Antiarrhythmic drug therapy in Heart Failure and Atrial Fibrillation, what is reasonable? Presented in the 8th International conference of the Egyptian Cardiac Arrhythmia Association (ECRA) on 23 October 2013TRANSCRIPT
![Page 1: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/1.jpg)
Antiarrhythmic drug therapy
in HF with AF, what is
reasonable
Prof. Samir Rafla, FACC, FESC
Alexandria Univ.
1
![Page 2: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/2.jpg)
![Page 3: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/3.jpg)
3
![Page 4: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/4.jpg)
Recommendations for Use of
Dronedarone (Multaq) in Atrial
Fibrillation
4
Class IIa
1.Dronedarone is reasonable to decrease
the need for hospitalization for
cardiovascular events in patients with
paroxysmal AF or after conversion of
persistent AF. Dronedarone can be
initiated during outpatient therapy.
(Level of Evidence: B
![Page 5: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/5.jpg)
Recommendations for Use of
Dronedarone in Atrial Fibrillation
5
Class III–Harm
1. Dronedarone should not be
administered to patients with class IV
heart failure or patients who have had an
episode of decompensated heart failure
in the past 4 weeks, especially if they
have depressed LV function (EF<35%).
(Level of Evidence: B)
![Page 6: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/6.jpg)
6
- The major adverse cardiac effects of
dronedarone are bradycardia and QT
prolongation. Torsades de pointes has
been reported.
- Like amiodarone, dronedarone inhibits
renal tubular secretion of creatinine,
which can increase plasma creatinine
levels. However, there is no reduction in
GFR.
- Dronedarone increases digoxin levels
1.7- to 2.5-fold.
![Page 7: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/7.jpg)
7
- Dronedarone is predominantly
metabolized by the liver (CYP3A4). It can
be administered with verapamil or
diltiazem, but low doses of these agents
should be used initially .
- Dronedarone does not alter the INR
when used with warfarin.
- The recommended oral dose of
dronedarone is 400 mg twice a day with
meals.
![Page 8: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/8.jpg)
Dronedarone - Adverse Events
Stroke 4 (0.5) 3 (0.7) 0.69
Cough
Dyspnea
19 (2.3) 7(1.7) 0.67
Hyperthyroidism
Hypothyroidism
67/801 (8.4)
44/801 (5.5
56/396 (14.1)
14/396 (3.5)
0.002
0.15
Abnormal LFTs 100/822 (12.2) 55/404(13.6) 0.52
Elev of Serum
Creatinine 20 (2.4) 1 (0.2) 0.004
Bradycardia
Heart Failure
22 (2.7)
20 (2.4)
8 (2.2)
4 (1.0)
0.56
0.12
VARIABLE DRONEDARONE
N=828
PLACEBO
N=409 P value
![Page 9: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/9.jpg)
Dronedarone - ATHENA: Summary
Dronedarone significantly prolongs time to first CV hospitalization or death in moderate- to high-risk AF patients
All-cause mortality was not increased in patients receiving dronedarone
CV mortality was lower in the dronedarone compared to the placebo group
The reduction in CV hospitalization was mainly due to fewer admissions for AF and acute coronary syndromes
The application of Dronedarone may be useful in low risk patients (only in NYHA Class I and II)
Hohnloser SH. Heart Rhythm Society 2008 Scientific Sessions;
May 15, 2008; San Francisco, CA.
![Page 10: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/10.jpg)
Atrial Fibrillation and Acute Decompensated
Heart Failure
10
Although the optimal resting HR during AF is
between 60 and 100 bpm, rates below 100 bpm
may not be achievable during AHDF until volume
overload and hypoxia have been corrected. A
more realistic target is to achieve a HR < 120
bpm during the first hours of treatment. Digoxin
should be the first rate-control agent considered.
If the patient has already been taking digoxin, add
doses only if serum digoxin concentration is <0.5
ng/mL.
![Page 11: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/11.jpg)
11
Cautious addition of small doses of an IV B blocker,
usually metoprolol in 2.5- to 5-mg increments or, if
systolic function is preserved, diltiazem will often be
required.
If rate control along with relief of volume overload
and dyspnea can be achieved, patients will
frequently revert back to SR if the AF episode is of
recent onset. If the patient does not improve with
these measures, meets anticoagulation criteria for
conversion, and if not already on an antiarrhythmic
drug, a trial of IV amiodarone may be helpful.
Atrial Fibrillation and Acute Decompensated
Heart Failure
![Page 12: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/12.jpg)
12
Amiodarone can be reloaded in patients already
on chronic, moderate doses (<200 mg daily) but
should not be added if the patient has been
taking another antiarrhythmic drug that prolongs
the QT interval, such as sotalol or dofetilide.
If this approach fails and heart rates during AF remain elevated, cardioversion after a period of loading with an antiarrhythmic drug, usually amiodarone, is the next step.
![Page 13: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/13.jpg)
Pharmacological Cardioversion of AF of up to 7 Days
Duration
13
Vernakalant IV or oral I
![Page 14: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/14.jpg)
![Page 15: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/15.jpg)
15
![Page 16: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/16.jpg)
![Page 17: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/17.jpg)
17
![Page 18: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/18.jpg)
![Page 19: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/19.jpg)
Torsade de Pointes
Occurs in 1% of patients taking Amiodarone
Predisposing conditions
– LVH, congestive heart failure
– Bradycardia
– Hypokalemia
– Hypomagnesemia
– Digitalis therapy
– Baseline QT prolongation
– High drug concentration (except quinidine)
![Page 20: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/20.jpg)
Patient Who Was Treated with Amiodarone for Atrial Fibrillation
![Page 21: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/21.jpg)
Treatment of Torsade de Pointes
Remove offending
agent
Temporary ventricular
or atrial pacing
Isoproterenol
– Increases rate and
decreases QT
interval
Lidocaine
Mexiletine
Phenytoin
Magnesium
![Page 22: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/22.jpg)
24 Porto-marina Beach - Egypt
![Page 23: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/23.jpg)
Flecainide (Tambocor) & propafenone (Rythmol®) Toxicity and Cautions for Class IC Drugs:
- They are proarrhythmic drugs causing worsening of a preexisting arrhythmia or de novo occurrence of life-threatening ventricular tachycardia
- Notice: Class 1C drugs are particularly of low safety and have shown even to increase mortality when used chronically after MI.
![Page 24: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/24.jpg)
With Sotalol (Betapace) and Dofetilide
(Tikosyn), the QT interval should be monitored
carefully during drug loading. Serum potassium
levels should also be watched carefully; in fact,
one should use torsades de pointes producing
agents with caution in patients requiring
potassium-wasting diuretics.
26
![Page 25: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/25.jpg)
Dofetilide (Tikosyn) had no effect on cardiac
output, cardiac index, or systemic vascular
resistance in patients with ventricular
tachycardia, mild to moderate congestive heart
failure .
Because increase in QT interval and the risk of
ventricular arrhythmias are directly related to
plasma concentrations of dofetilide, dosage
adjustment based on calculated creatinine
clearance is critically important
27
![Page 26: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/26.jpg)
28 Ras Sidr Beach. Saini. Egypt
![Page 27: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/27.jpg)
Vernakalant is a sodium channel blocker (I
Na) and a potassium channel blocker.
In ACT study, adverse events were reported in
32% of placebo recipients and 38% of
Vernakalant recipients. No deaths or torsade
de points were reported.
29
Atrial Specific AADs
![Page 28: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/28.jpg)
Vernakalant BRINAVESS is contraindicated
in patients with severe aortic stenosis, systolic
BP<100 mm Hg, and heart failure class III and
IV.
Vernakalant is contraindicated in patients with
prolonged QT at baseline (uncorrected >440
msec), severe bradycardia, sinus node
dysfunction, or second-degree or third-degree
heart block in the absence of a pacemaker.
30
![Page 29: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/29.jpg)
Vernakalant is also contraindictated in patients
who use IV rhythm control antiarrhythmics
(class I and class III) within 4 hours prior to
administration of Vernakalant and patients with
acute coronary syndrome (including myocardial
infarction) within the last 30 days.
Adverse reactions (>5%) seen in the first 24
hours after receiving Vernakalant were taste
disturbance (20.1%), sneezing (14.6%), and
paraesthesia (9.7%).
31
![Page 30: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/30.jpg)
![Page 31: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/31.jpg)
![Page 32: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/32.jpg)
![Page 33: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/33.jpg)
![Page 34: Samir rafla antiarrhythmic drug therapy in hf and af , what is reasonable](https://reader034.vdocuments.us/reader034/viewer/2022052523/55505fc1b4c905c0448b50dc/html5/thumbnails/34.jpg)
36 Ain Sokhna – Stella di Mare Hotel and Beach - Egypt